G1 Therapeutics, Inc

G1 Therapeutics, Inc. is a commercial-stage oncology company focused on the development and commercialization of next generation anti-cancer therapies. Led by a team with a deep understanding of the biology of cancer and extensive development and commercialization expertise, G1 is advancing its mission to improve the lives of those affected by cancer, including by commercializing the Company’s first commercial product, COSELA® (trilaciclib). G1 is also executing a development program, with a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics. View our social community guidelines here: